Plain-English translation of NCT07002216 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination chemotherapy regimen called BrECADD—which includes the medication plus five other chemotherapy drugs—in people with advanced Hodgkin lymphoma. The goal is to see how well this treatment works and how well patients tolerate it. The study will also explore whether a simple blood test can help doctors measure how well the treatment is working.
Hodgkin lymphoma is a serious cancer of the immune system, and while current treatments exist, researchers want to find better combinations that are more effective and help patients live longer. This medication combines a newer targeted drug with traditional chemotherapy to potentially improve outcomes for people with advanced disease.
You likely qualify if…
You likely don't qualify if…
You would receive the BrECADD medication combination at the recommended doses, which is typically given intravenously as a chemotherapy regimen. Your participation would last up to 24 months (2 years) and would involve regular clinic visits for infusions, blood tests, and imaging scans to monitor how you're responding to treatment. You would also have blood drawn periodically to check for circulating tumor DNA, a new type of test that helps doctors see how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States